content_top
43 companies, 1 interpreter! Insight, foresight
and recommendation 

BioTime, Inc. (BTX)

2.84
0.01
(0.35%)
Sep 11, 4:00PM EDT
content_middle

BioTime, Inc., a biotechnology company, focuses on regenerative medicine and blood plasma volume expanders. The company primarily focuses on regenerative medicine, which refers to therapies based on human embryonic stem cell and induced pluripotent stem cell technology designed to rebuild cell and tissue function lost due to degenerative disease or injury. It develops and markets research products in the field of stem cells, including an array of proprietary PureStem cell lines and associated ESpan culture media, HyStem hydrogels, and differentiation kits, as well as offers Hextend, a blood plasma volume expander. The company is developing Renevia, a biocompatible, implantable hyaluronan, and collagen-based matrix for cell delivery in human clinical applications; stem cell-based therapies for retinal and neural degenerative diseases; and therapies to treat orthopedic disorders, diseases, and injuries. It is also developing PanC-Dx, a non-invasive blood-based cancer screening test; and therapeutic products for cardiovascular and blood diseases and disorders. In addition, the company markets GeneCards, a human gene database. Further, it is developing an integrated database suite to complement GeneCards that would include the LifeMap database of embryonic development, stem cell research, and regenerative medicine, as well as MalaCards, the human disease database. BioTime, Inc. was founded in 1990 and is headquartered in Alameda, California.

Previous Close: 
2.83
Open: 
2.87
Bid: 
2.84
Ask: 
2.99
1yr Target Price: 
6.17
Day's Range: 
2.81 - 2.88
52wk Range: 
2.47 - 4.01
Volume: 
179025
Average Daily Volume: 
353887
Market Capitalization: 
328.88M
Trailing Annual Dividend Yield: 
N/A
Shares Outstanding: 
115804000M
content_right

Pages